Retatrutide vs Tirzepatide: how does the research compare?
Both compounds are reviewed against the same standard: what has been studied, in whom, and what the studies reported. Human evidence and preclinical evidence are kept separate throughout.
Research education only — not medical advice
Retatrutide
Triple agonist (GLP-1 / GIP / glucagon)
- Human research
- Strong
- Preclinical research
- Moderate
Emerging — Phase 3 trials still in progress.
Full research profileTirzepatide
Dual agonist (GIP / GLP-1)
- Human research
- Extensive
- Preclinical research
- Strong
Established — approved and in wide clinical use.
Full research profileThe Wize summary
- What each is
Retatrutide
Triple agonist (GLP-1 / GIP / glucagon)
Tirzepatide
Dual agonist (GIP / GLP-1)
- Human evidence
Retatrutide
strong
Tirzepatide
extensive
- Preclinical evidence
Retatrutide
moderate
Tirzepatide
strong
- What remains unknown
Retatrutide
Emerging — Phase 3 trials still in progress.
Tirzepatide
Established — approved and in wide clinical use.
Bottom line
Human research for Retatrutide is rated strong, and for Tirzepatide it is rated extensive. That rating describes how much human research exists — not whether either compound works, and not whether either is safe.
How these two relate.
Tirzepatide's two targets (GLP-1R, GIPR) are both contained within retatrutide's three targets — the overlap is substantial.
Detail by dimension.
Compound class
- Retatrutide
- Triple agonist (GLP-1 / GIP / glucagon)
- Tirzepatide
- Dual agonist (GIP / GLP-1)
Mechanism being investigated
- Retatrutide
- Activates three receptors simultaneously: GLP-1, GIP, and glucagon receptors. The glucagon component distinguishes it from dual agonists and adds reported effects on energy expenditure.
- Tirzepatide
- Activates both GIP and GLP-1 receptors. The GIP component is reported to contribute additional effects on fat metabolism beyond GLP-1R agonism alone.
Receptor targets
- Retatrutide
- GLP-1 receptor; GIP receptor; Glucagon receptor
- Tirzepatide
- GIP receptor; GLP-1 receptor
Research areas
- Retatrutide
- Metabolic research, Appetite signaling, Body composition
- Tirzepatide
- Metabolic research, Appetite signaling, Body composition
Half-life, as reported
- Retatrutide
- ≈ 6 days (reported from Phase 2 pharmacokinetic analyses)
- Tirzepatide
- ≈ 5 days (≈ 120 hours, reported in PK studies)
Human research
- Retatrutide
- Strong — A Phase 2 randomized trial (24–48 weeks) reported dose-dependent weight reduction and improved cardiometabolic markers. Phase 3 is ongoing.
- Tirzepatide
- Extensive — Extensive Phase 3 program (SURPASS trials) in type 2 diabetes and the SURMOUNT trials for weight management; regulatory approval in multiple jurisdictions.
Preclinical research
- Retatrutide
- Moderate — Preclinical studies in obese animal models reported combined effects on appetite and energy expenditure.
- Tirzepatide
- Strong — Well-characterized in diet-induced obesity models.
Mechanistic research
- Retatrutide
- Strong — Receptor pharmacology is well characterized in vitro and in animal models.
- Tirzepatide
- Strong — Receptor pharmacology and relative potency are published.
What studies reported
- Retatrutide
- In a 2023 Phase 2 trial (New England Journal of Medicine), participants showed substantial dose-dependent weight reduction over 24–48 weeks, the largest reported for a peptide at that stage.
- Tirzepatide
- Phase 3 trials reported significant weight reduction and HbA1c improvement, outperforming active comparators including semaglutide in head-to-head trials.
Reported adverse effects in studies
- Retatrutide
- Most commonly reported trial events were gastrointestinal (nausea, vomiting, diarrhea), dose-dependent.
- Tirzepatide
- Most commonly reported in trials: gastrointestinal events (nausea, diarrhea, vomiting), dose-dependent.
Research maturity
- Retatrutide
- Emerging — Phase 3 trials still in progress.
- Tirzepatide
- Established — approved and in wide clinical use.
Study records.
Published research already verified into the Wize study library. Each record carries its own design, findings, and limitations.
Retatrutide
No verified study record for Retatrutide is in the Wize library yet. Records are added only once the publication has been checked against its source.
Sources & research.
These are search and registry entry points, not endorsements. Every finding above should be checked against the primary publication before it is relied on.
What this comparison cannot settle.
A comparison of research is not a comparison of treatments. Where a study has directly compared Retatrutide with Tirzepatide, it appears above with a link to its record; where none appears, we have not identified one. Neither compound's evidence base can say which is more appropriate for any person, at any dose, or in any situation — and the letter on each card measures how much human research exists, not how well anything works.
Continue researching.
Continue comparing.
Get a new guide every week.
Subscribe free and the Beginner's Guide, the COA Guide, and the Safety Guide are yours the moment you sign up.